<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Endocrine Disorders by danielle Coddington</title>
      <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh</link>
      <description>Made with a dash of wit</description>
      <language>en-us</language>
      <pubDate>2017-10-18 14:20:45 UTC</pubDate>
      <lastBuildDate>2024-05-18 10:58:13 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Anterior pituitary hormones/growth hormones</title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200102812</link>
         <description><![CDATA[<div> The anterior pituitary gland produces the following hormones and releases them into the bloodstream:<em><mark><br></mark></em><br></div><ul><li>adrenocorticotropic hormone, which stimulates the adrenal glands to secrete steroid hormones, principally <a href="http://www.yourhormones.info/hormones/cortisol/">cortisol</a><br>  </li><li>growth hormone, which regulates growth, metabolism and body composition<br>  </li><li>luteinising hormone and <a href="http://www.yourhormones.info/hormones/follicle-stimulating-hormone/">follicle stimulating hormone</a>, also known as gonadotrophins. They act on the ovaries or testes to stimulate sex hormone production, and egg and sperm maturity<br>  </li><li>prolactin, which stimulates milk production<br>  </li><li>thyroid stimulating hormone, which stimulates the <a href="http://www.yourhormones.info/glands/thyroid-gland/">thyroid</a> gland to secrete thyroid hormones.</li></ul><div><br>PROTOTYPE</div><div> </div><div>Somatropin </div><div> </div><div>Expected outcome: Stimulate overall growth and the production of protein, and decrease the use of glucose. </div><div> </div><div>Therapeutic use: treats growth hormone defeiencies ( pediatric and adult growth hormone defeincy, turners syndrome)</div><div>AIDS wasting syndrome</div><div> </div><div>Complications: Hyperglycemia , Hypercalciuria and renal calculi</div><div> </div><div>Client education: Monitor glucose leves, Montior for flank pain, fever and dysuria</div><div> </div><div>Contradindications/Precautions: Pregnancy risk B or C (depdens on the brand)</div><div>Contraindicated in obesesity and sleep apnea patients</div><div>Use cautiously in clients with hypothyrioism – evaluate thyroid functions prior to</div><div> </div><div>Interactions: concurrent use of glucocorticoids can counteract growth- promoting effects </div><div> </div><div>Nursing Administration: Obtain baseline height and weigh, monoitor growth patterns monthly, Rotate injection site <br><br>NCLEX question<br><br>A nurse is caring for a client who is taking somatropin to stimulate growth. The nurse should plan to monitor the clients urine for which of the following?<br>A. Billrubin<br>B. Protein<br>C. Potassium<br>D. Calcium<br><br><br><br><br><br>Answer:<br>D. Calcium<br><br>A large amount of calcium can be present in the urine of a client who takes somatropin. This puts them at risk for renal calculi</div>]]></description>
         <enclosure url="" />
         <pubDate>2017-10-24 17:09:17 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200102812</guid>
      </item>
      <item>
         <title>Antidiurectic hormone</title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200105047</link>
         <description><![CDATA[<div><br></div><div>Vasopressin</div><div> Other medication Desmopressin </div><div> </div><div>Expected outcome: ADH (anti diuretic hormone) produced by the hypothalamus and stored in the posterior pituary,, promoted reabsorption of water into the kidney, while desmopressin causes much less vasoconstriction</div><div> </div><div>Natural ADH causes vasoconstriction due to the contraction of vascular smooth muscle.  Vasopressin stimulates the potent action of ADH. </div><div> </div><div>Therapeutic use:  treats Diabetes Insipidus </div><div>(desmopressin)</div><div>Vasopressin sometimes used during CPR to temporaily decrease blood flow to the peripheray and increase flow to brain and heart<br> <br> </div><div>Administration: Desmopressin – Oral, Intra nasal, SUB Q , IV</div><div>Vasopressin- SUB Q, IM, IV </div><div> </div><div>Complications: Reabsoprtion of too much water </div><div>Nursing considerations; monitor for over hydration (sleepiness, pounding headache), teach clients to reduce fluid intake during therapy,</div><div> </div><div>Myocardial Ischemia</div><div>From excessive vasoconstriction( vasopressin)</div><div>Nursing consideration- monitor ECG and blood pressure, advise client to notify HCP of chest pain, tightness or diaphoresis</div><div> </div><div>Contraindications/precautions :</div><div>Use of vasopressin contraindicated in clients with CAD, decreased peripheral circulation or chornic nephritis. </div><div>Vasopressin catergory risk C </div><div>Desmopression catergory risk B</div><div>Use caution in clients who have renal impairment  - ADH should not be administered to clients who have creatinine clearance less than 50ML/min </div><div> </div><div>Interactions</div><div>Carbamazepine and tricyclic antidepressants can increase the antidiuretic action</div><div>Nursing considerations:  use cautiously together</div><div> </div><div>Con current use of alcohol,  heparin,  lithium,  and phenytoin can decrease the antidiuretic effects</div><div>Nursing consideration:  established baseline I&amp;O and weight,  Monitor frequently</div><div> </div><div>Nursing administration:</div><div>Monitor vital signs, Central venous pressure, I&amp;O, specific gravity, and laboratory studies( potassium,  sodium, BUN, creatinine,  specific gravity, osmality)</div><div>Monitor for headache confusion for other indications of water intoxication</div><div>With IV administration of vasopressin,  Monitor the IV site carefully because extravastration can lead to gangrene</div><div>Intranasal desmopressin starts with the bedtime dose. I &amp;O is monitored</div><div>.  When nocturia is controlled doses are given twice daily</div><div> </div><div> </div><div>Nursing evaluation of medication effectiveness</div><div>Reduction in the large volumes of urine output (1.5-2L in 24 hours)</div><div>Cardiac arrest survival</div><div> </div><div> </div>]]></description>
         <enclosure url="" />
         <pubDate>2017-10-24 17:13:18 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200105047</guid>
      </item>
      <item>
         <title>Adrenal hormone replacement</title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200105428</link>
         <description><![CDATA[<div>Proto type: hydrocortisone</div><div> </div><div> </div><div> </div><div>Expected action:  mimic effects of natural steroid hormones</div><div> </div><div>Therapeutic use: acute and chronic replacement therapy for adrenocortical insufficiency ( addisons disease, adrenal crisis)</div><div>Non-ended grin disorders including cancer,  inflammation,  and allergic reaction</div><div> </div><div>Route of administration: oral, IV</div><div> </div><div>Complication:</div><div>Osteoporosis</div><div>Advise clients to take calcium supplements vitamin D and or bio phosphonate and get regular exercise</div><div> </div><div>Adrenal suppression</div><div>Advised client to observe for Manifestations ( fatigue, weakness, weight loss hypotension)</div><div>Increase dose with stress.  Do not stop suddenly. Tapered dose to discontinue. </div><div> </div><div>Peptic ulcer,  G.I. discomfort</div><div>Advise client to observe for Manifestations ( coffee ground emesis,  bloody or tarry stools,  abdominal pain)</div><div>Administer prophylactic H2 receptor antagonist</div><div> </div><div>Infection</div><div>Advise clients to avoid contact with people who have a communicable disease</div><div>Monitor for any indication of infection such as fever</div><div> </div><div>Cushing syndrome</div><div>Risks are associated with long-term use of glucocorticoids and excessive doses. </div><div>Advise client to observe for Manifestations ( muscle weakness,  Moon face,  Buffalo hump, cutaneous striations)</div><div> </div><div> </div><div>Contraindications/ precautions</div><div>Pregnancy risk category C</div><div>Use is contraindicated in clients to have a viral bacterial or fungal infection is not controlled by antibiotics</div><div>Using caution with clients who have had in recent and MI gastric ulcer hypertension kidney disorder osteoporosis diabetes mellitus hypothyroidism myasthenia gravis glaucoma or seizure disorder</div><div> </div><div>Interaction</div><div>NSAIDs,  acetaminophen or alcohol can cause increased gastric distress  distress or bleed</div><div> Concurrent use with oral anti coagulants can increase/decrease anticoagulation</div><div>Concurrent use with potassium depleting agents can cause increased potassium loss</div><div>Concurrent use with vaccines and toxoids can reduce the antibody response</div><div> </div><div>Nursing administration</div><div>Monitor weight blood pressure and electrolytes</div><div>Given with food to reduce gastric distress</div><div>Advise client to monitor for indications of peptic ulcer</div><div>Do not stop medication suddenly , tapper dose if  discontinuing</div><div>Advised provider of indications of acute adrenal insufficiency</div><div>instruct clients that dosages need to be increased during times of stress</div><div>Advise clients that replacement therapy for Addison’s disease must continue for life</div><div>Instruct client to carry an extra supply of glucocorticoids for emergencies into wear medical identification at all times</div><div> <br><br>Evidence Based Article. <br><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa071366#t=article">http://www.nejm.org/doi/full/10.1056/NEJMoa071366#t=article</a></div><div> </div>]]></description>
         <enclosure url="" />
         <pubDate>2017-10-24 17:14:01 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200105428</guid>
      </item>
      <item>
         <title>Hyperpituitarism  </title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200200749</link>
         <description><![CDATA[<div><br><strong>Hyperpituitarism</strong> is a condition due to the primary hypersecretion of pituitary hormones<br><br></div><div>Prototype Octreotide&nbsp;</div><div>&nbsp;</div><div>Expected action: suppresses growth hormone release</div><div>&nbsp;</div><div>therapeutic uses:&nbsp; gigantism in children acromegaly in adults<br><br>Route of administration: IM or Sub Q</div><div>&nbsp;</div><div>Complications: G.I. disturbances ( nausea cramps diarrhea and flatulence)</div><div>Nursing considerations:&nbsp; advise client’s symptoms usually subside 1-2&nbsp; weeks,</div><div>Given injections without food or at bedtime to minimize symptoms</div><div>&nbsp;</div><div>Hypo/ hyperglycemia</div><div>Nursing considerations:&nbsp; monitoring glucose levels regularly</div><div>&nbsp;</div><div>&nbsp;</div><div>Contra indications/ precautions</div><div>Pregnancy risk category B</div><div>Use cautiously in client who have diabetes,&nbsp; hypothyroidism,&nbsp; renal disease,&nbsp; and in older adults</div><div>&nbsp;</div><div>Interaction: conduction delay can occur if used with anti dysrhythmics&nbsp;</div><div>&nbsp;</div><div>&nbsp;</div><div>Nursing administration:&nbsp; teach client proper technique for sub Q injection</div><div>Minimize injection site pain by rotating sites</div><div>&nbsp;</div><div>Nursing evaluation of medication effectiveness: depending on therapeutic intent evidence of effectiveness can include the suppression of excess growth hormone for the management of acromegaly when surgery or radiation has failed</div><div>&nbsp;</div><div>&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2017-10-24 20:39:46 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200200749</guid>
      </item>
      <item>
         <title></title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200446663</link>
         <description><![CDATA[<div>Gigantism </div>]]></description>
         <enclosure url="https://padletuploads.blob.core.windows.net/prod/231018914/4ceaa0241d93b8010711b804a77f6563/Gigantism_Causes_and_Symptoms_of_the_Disease.jpg" />
         <pubDate>2017-10-25 15:01:48 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/200446663</guid>
      </item>
      <item>
         <title>Pituitary Gland </title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201700779</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padletuploads.blob.core.windows.net/prod/231018914/629fe3f9c8a70cf3ab845c7ce84113bc/pituitary_2.gif" />
         <pubDate>2017-10-30 13:19:29 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201700779</guid>
      </item>
      <item>
         <title>Growth hormone defiency </title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201702497</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padletuploads.blob.core.windows.net/prod/231018914/8afb4a423e6d9789a25921e74a9add8e/Growth_hormone_deficiency.jpg" />
         <pubDate>2017-10-30 13:22:59 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201702497</guid>
      </item>
      <item>
         <title>Addisons Disease</title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201706256</link>
         <description><![CDATA[<div>Hyper pigmentation</div>]]></description>
         <enclosure url="https://padletuploads.blob.core.windows.net/prod/231018914/42aff68c6f6248bf13777437e92ccabc/505_hyperpigmentation_of_addison_disease_s101_springer_high.jpg" />
         <pubDate>2017-10-30 13:29:30 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201706256</guid>
      </item>
      <item>
         <title>References</title>
         <author>coddingtondanielle</author>
         <link>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201716424</link>
         <description><![CDATA[<div>Henry, Norma Jean E, et al. “Chapter 40 Endocrine Disorders.” <em>RN Pharmacology for Nursing Review Module</em>, 7.0 ed., Assessment Technologies Institue LLC, 2016, pp. 315–324.<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2017-10-30 13:48:56 UTC</pubDate>
         <guid>https://padlet.com/coddingtondanielle/9z03j1k9t7sh/wish/201716424</guid>
      </item>
   </channel>
</rss>
